BCT:CC News and Press, Briacell Therapeutics Corp. From 12/28/23

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI) Tumor reductions observed in heavily pretreated patient...

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar studies* Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinica...

VersaBank (VBNK:CA) is expected to report $0.44 for Q4 2023 Genesis Land Development Corp. (GDC:CA) is expected to report for Q2 2024 Aberdeen International Inc. (AAB:CA) is expected to report for Q1 2024 Crown Capital Partners Inc. (CRWN:CA) is expected to report for Q1 2024 Diam...

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*). 32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. ...

BriaCell’s Bria-IMT ™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET imaging Advanced protein array technologies showed unique ant...

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded. Heavily treated patient had 7 prior failed regimens ....

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies Data supports further development of BriaCell’s next generation personalized immunotherapy platform with potent ant...

Canadian Critical Minerals Inc. (CCMI:CA) is expected to report for quarter end 2023-08-31 Advantage Energy Ltd. (AAV:CA) is expected to report $0.16 for Q3 2023 Canadian Utilities Limited Class A Non-Voting Shares (CU:CA) is expected to report for Q3 2023 Newmont Corporation (NGT:CA)...

BriaCell Therapeutics Corp. (BCT:CA) is expected to report $-0.52 for Q4 2023

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...